A Catalio-initiated liquid biopsy diagnostic company developing a best-in-class assay for the detection of minimal residual disease (MRD) to improve cancer patient outcomes.
Surgery remains the standard of care for most early-stage solid tumors, but most cancers recur. Tracking progression of disease after treatment remains challenging, and it can be months or years before recurrent disease is detected by routine diagnostic work ups. Haystack’s bespoke liquid biopsy assay detects a patient’s tumor-specific markers via blood sample to identify residual disease following treatment. The company’s patented technology offers best-in-class sensitivity resulting in earlier detection of recurrent disease and improved outcomes for millions of cancer patients each year.